Archives
- 2018-07
- 2018-10
- 2018-11
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
-
Covalent inhibitors are well suited for targeting the
2019-09-23
Covalent inhibitors are well suited for targeting the E1 GDC0199 kinase of Ubl modifications. Because the E1 enzymes in Ubl modifications, such as the SUMO E1 and Atg7, have a slow turnover rate (Boggio et al., 2004), prolonged inhibition can be achieved without requiring compounds to be stable in c
-
Current therapeutic interventions are directed both to preve
2019-09-23
Current therapeutic interventions are directed both to prevent (primarily by proper glycemic control) and to treat the advanced stages of diabetic retinopathy, when vision has already been significantly affected. Although these therapies can be very effective in preventing, delaying or reducing visi
-
The IV chains of mature GBM are built exclusively by
2019-09-23
The α3/α4/α5(IV)-chains of mature GBM are built exclusively by podocytes (not by endothelial cells) (Abrahamson et al., 2009), placing the podocytes into the focus of GBM-diseases such as Alport syndrome. Alport syndrome (AS) is caused by mutations in the COL4A3, 4 or 5 genes coding for the α3/α4/α5
-
Steady state mRNA levels of CYP A
2019-09-23
Steady-state mRNA levels of CYP3A isoforms were not changed during liver insufficiency. Suppression of these isoforms was observed only at the protein and activity levels, suggesting a nongenomic mechanism of CYP3A isoform downregulation during liver insufficiency. Nonetheless, transcriptional activ
-
The mammalian two hybrid results described above were all
2019-09-23
The mammalian two-hybrid results described above were all obtained in 293T cells, and thus the higher RLU observed specific to the hCrm1 fusion could be consistent with human 2 hydroxyglutarate clinical having an unknown activator that interacts with hCrm1 HEAT repeat 9A and somehow facilitates Crm
-
Within the Class II receptors the Type I IFN receptor
2019-09-23
Within the Class II receptors, the Type I IFN receptor subunit, IFNAR-1, is exceptional in having four tandem FNIII domains, denoted here D1–D4. This structure appears to have arisen as a tandem Isorhamnetin pathway of the basic D1/D2 structure; thus, D1 and D3 of IFNAR-1 are more closely related,
-
Under optimized assay conditions very low concentrations pM
2019-09-23
Under optimized assay conditions, very low concentrations (20pM) of [125I]YP20 bound to hCRF1-CHO SGC707 pathway membranes with high specificity (>95% inhibited by 1μM astressin) and in a membrane protein-dependent manner. Specific binding was selective vs. the hCRF2α subtype because little specific
-
br Author contribution br Acknowledgements QNRF grant number
2019-09-23
Author contribution Acknowledgements QNRF grant number NPRP6-065-3-012, Qatar National Research Fund, Doha Qatar for funding this work with grant number NPRP No.: NPRP6-065-3-012. Introduction Preeclampsia (PE) affects 3–5 % of pregnancies worldwide and is one of the leading causes of mate
-
Wu et al explored the anti inflammatory mechanisms
2019-09-23
Wu et al. explored the anti-inflammatory mechanisms by which osthole 35 acted on HepG2 cells cultured in a differentiated medium from cultured 3T3-L1 preadipocyte cells. HepG2 cells, a human liver cell line, were treated with various concentrations of osthole 35 in differentiated media from cultured
-
Quercitrin br Acknowledgments We thank the Lapaha Community
2019-09-23
Acknowledgments We thank the Lapaha Community and Nobles (His Serene Highness Prince Kalaniuvalu Fotofili, Her Serene Highness Princess Marcella Taumoepeau Tupou Kalaniuvalu Fotofili and Her Royal Highness Mele Siu\'ilikutapu Kalaniuvalu Fotofili) and the Ministry of Internal Affairs (Government
-
br Patients and methods br Results Table shows relevant
2019-09-23
Patients and methods Results Table 1 shows relevant demographic and clinical characteristics of the 123 patients in the cohort. BAL fluid samples were obtained at a median of 172.5 days after allo-HSCT (range 3 days to five years). Discussion The definitive abandonment of traditional cultu
-
parp apoptosis pathway Increasing age among middle aged
2019-09-23
Increasing age among middle-aged subjects (30–59years old) was associated with higher levels of cholesterol synthesis markers (although without statistical significance) and also of cholesterol parp apoptosis pathway markers (with statistical significance for campesterol and sitosterol); this findi
-
Data from immunohistochemical detection of CIC
2019-09-23
Data from immunohistochemical detection of CIC-3 revealed that the immunostaining of CIC-3 can be present both in hepatocarcinoma and its matched normal controls though; CIC-3 was, on the whole, significantly elevated in hepatocarcinoma relative to its paired normal control. In consideration of the
-
Despite the sources of error discussed above several
2019-09-23
Despite the sources of error discussed above, several trends have emerged and much valuable data are available regarding binding affinities of progestogens for different steroid receptors. All the progestogens bind to the PR with a high affinity, typically in the nanomolar range. For example the syn
-
Targeting the MAPK pathway has attracted
2019-09-23
Targeting the MAPK pathway has attracted significant interest in cancer therapy. Efforts directly targeting RAS protein are believed to be very challenging in spite of the promise shown by a few RAS inhibitors in the early development stage. Clinical benefits achieved by BRAF and MEK inhibitors have
15669 records 930/1045 page Previous Next First page 上5页 926927928929930 下5页 Last page